Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

V4758

Sigma-Aldrich

Monoclonal Anti-Vascular Endothelial Growth Factor antibody produced in mouse

clone 26503, purified immunoglobulin, lyophilized powder

Sinónimos:

Anti-VEGF

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

MDL number:
MFCD00282511
UNSPSC Code:
51111800
NACRES:
NA.41

biological source

mouse

Quality Level

200

conjugate

unconjugated

antibody form

purified immunoglobulin

antibody product type

primary antibodies

clone

26503, monoclonal

form

lyophilized powder

species reactivity

primate, human

technique(s)

capture ELISA: 2-8 μg/mL
neutralization: suitable
western blot: 1-2 μg/mL

isotype

IgG2b

UniProt accession no.

P15692

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... VEGFA(7422) , VEGFB(7423) , VEGFC(7424)

General description

The antibody will neutralize the biological activity of recombinant human VEGF165. It also recognizes VEGF121.

Immunogen

purified recombinant Sf21-derived human VEGF (165 aa isoform).

Application

Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below.
Western Blotting (1 paper)
Monoclonal Anti-Vascular Endothelial Growth Factor antibody produced in mouse was used to block the interaction between VEGF and kinase domain receptor in Calf Pulmonary Aortic Endothelial (CPAE) cells.

Biochem/physiol Actions

The vascular endothelial growth factor family consists of five members, VEGF-A to VEGF-E. They play important roles in important role in embryonic vasculogenesis, angiogenesis and homeostasis. The interaction between VEGFs and their respective receptors results in the activation of MAPK, PI3K, PKC, FAK and Src kinase pathways.

Physical form

Lyophilized from a 0.2 μm solution in phosphate buffered saline containing carbohydrates.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

¿No encuentra el producto adecuado?  

Pruebe nuestro Herramienta de selección de productos.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Dong-Kwon Lim et al.
Biomaterials, 77, 130-138 (2015-11-21)
Vascular endothelial growth factor 165 (VEGF165) is an important extracellular protein involved in pathological angiogenesis in diseases such as cancer, wet age-related macular degeneration (wet-AMD) and retinitis pigmentosa. VEGF165 exists in two different isoforms: the angiogenic VEGF165a, and the anti-angiogenic
R Binétruy-Tournaire et al.
The EMBO journal, 19(7), 1525-1533 (2000-04-04)
Vascular endothelial growth factor (VEGF) binding to the kinase domain receptor (KDR/FLK1 or VEGFR-2) mediates vascularization and tumor-induced angiogenesis. Since there is evidence that KDR plays an important role in tumor angiogenesis, we sought to identify peptides able to block
A Ohwada et al.
Thorax, 58(4), 328-332 (2003-04-02)
Acid induced pneumonitis resulting in acute respiratory distress syndrome (ARDS) is characterised by increased alveolar permeability and accumulation of neutrophils. It is hypothesised that vascular endothelial growth factor (VEGF) is involved in the development of lung oedema. Furthermore, lower levels
Esther Grueso et al.
Journal of virology, 93(19) (2019-07-19)
As many tumor cells synthetize vascular endothelial growth factors (VEGF) that promote neo-vascularization and metastasis, frontline cancer therapies often administer anti-VEGF (α-VEGF) antibodies. To target the oncolytic parvovirus minute virus of mice (MVM) to the tumor vasculature, we studied the
Tania Calvo-López et al.
Frontiers in microbiology, 13, 1063706-1063706 (2023-02-10)
Parvoviruses are promising anticancer and gene therapy agents, but a deep knowledge of the entry process is crucial to exploit their therapeutic potential. We addressed this issue while attempting to retarget the oncolytic parvovirus minute virus of mice (MVMp) to
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico